This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit
Organizer(s): Padmanee Sharma, Aviv Regev, Crystal L. Mackall and Kristen Hege
Date: March 10 - 14, 2019
Location: Whistler Conference Centre, Whistler, BC, Canada
Sponsored by Autolus Therapeutics, Bayer AG, BioLegend, Inc., Bristol-Myers Squibb Company, Cell Research, ImmunoGen, Inc., Incyte Corporation, MedImmune, Merck & Co., Inc., Roche, Surface Oncology, TESARO, Inc., Takeda Pharmaceutical Company Limited and Tessa Therapeutics Ltd.
Summary of Meeting:
Cancer immunotherapy is an established field that has led to remarkable clinical benefit for a subset of patients. However, a deeper understanding of the mechanisms of response and resistance to current immunotherapy strategies is needed to help develop new treatments that will increase the number of patients who will benefit. This Keystone Symposia conference is focused on immunotherapy as a treatment for cancer, including potential combination therapies and development of new technologies to elucidate novel targets and/or biomarkers that will be used to design new treatments and enable appropriate patient selection to improve clinical outcomes for cancer patients. The conference will bring together leading and emerging scientists to advance the development of new immune-based treatments for cancer. Discussions will also consider the future directions of the field, including the identification of the most pressing unanswered questions, the areas needing more focus, and those that would benefit from new approaches and methodologies developed and used in other related fields.
Scholarship Deadline: November 20 2018
Discounted Abstract Deadline: November 20 2018
Abstract Deadline: December 5 2018
Discounted Registration Deadline: January 15 2019
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Autolus TherapeuticsBayer AGBioLegend, Inc.Bristol-Myers Squibb CompanyCell ResearchImmunoGen, Inc.Incyte CorporationMedImmuneMerck & Co., Inc.RocheSurface OncologyTakeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company LimitedTESARO, Inc.Tessa Therapeutics Ltd.
We gratefully acknowledge additional support from these exhibitors at this conference:
PeproTech, Inc.10x Genomics
We gratefully acknowledge additional support for this conference from:
American Association for Cancer Research (AACR)American Society of Gene & Cell Therapy (ASGCT)eLifeInSphero Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Amgen Inc.

Arcus Biosciences, Inc.

Celgene Corporation

Forty Seven, Inc.

Jounce Therapeutics, Inc.

Kyn Therapeutics

Nektar Therapeutics
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13CA236284-01
Funding for this conference was made possible (in part) by 1R13CA236284-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found